As gene therapies for various forms of retinal degeneration progress toward human clinical trial, it will be essential to have a repertoire of safe and efficient vectors for gene delivery to the target cells. Recombinant adeno-associated virus (AAV) serotype 2/2 has been shown to be well tolerated in the human retina and has provided efficacy in human patients for some inherited retinal degenerations. In this study, the AAV2/8 and AAV2/rh10 serotypes have been compared as a means of gene delivery to mammalian photoreceptor cells using a photoreceptor specific promoter for transgene expression. Both AAV2/8 and AAV2/rh10 provided rescue of the retinal degeneration present in the rhodopsin knockout mouse, with similar levels of benefit as evaluated by molecular, histological, and functional readouts. Transgene expression levels were significantly higher (fivefold) 1 week postsubretinal injection when employing AAV2/8 for rhodopsin gene delivery compared to AAV2/rh10, and were indistinguishable by 6 weeks postadministration of vector. This study reports the use of the AAV2/rh10 serotype to provide rescue in a degenerating retina and provides a comparative evaluation of AAV2/rh10 with respect to AAV2/8, a serotype regarded as providing efficient delivery to photoreceptors.
INTRODUCTION
Gene therapies for ocular disorders have been spearheaded by clinical trials for Leber congential amaurosis (LCA) linked to RPE65. Notably, gene replacement of the RPE65 gene provided benefit in patients with this early-onset retinal dystrophy. [1] [2] [3] The success of the LCA trials is not only relevant in its own context but has also greatly advanced the wider ocular gene therapy field. Significantly, these trials showed not only some efficacy, but also importantly the tolerance of the eye to the delivery vector, an adeno-associated virus (AAV). This small nonpathogenic parvovirus can transduce many cell types including nondividing terminally differentiated cells such as neurons. The eye has proved to be an excellent model organ for gene therapy treatment because of its accessible nature and its immune privileged state. 4, 5 The value of AAV for gene delivery to the retina has been further supported by a recent phase 1 trial for Choroideremia in which beneficial effects were obtained. 6 A number of hybrid AAV vectors have been engineered with different AAV capsid proteins to provide different tropisms and optimal transduction efficiencies for various target cell types. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] In the retina, AAV tropism has been assessed and transduction efficiencies in different cell types compared. 7, 8, 10, 13, [18] [19] [20] [21] It has been found that a number of AAV serotypes transduce retinal pigment epithelial (RPE) cells (AAV 2/1, 2/2, 2/5, 2/7, 2/8, and 2/9) and horizontal cells (2/1, 2/2, 2/8, 2/9, and 2/10) efficiently. Photoreceptor cells are readily transduced by serotypes 2/1, 2/5, 2/7, 2/8, 2/9, and 2/11 following subretinal injection, with AAV 2/8 regarded as the most efficient in this cell type. 1, 13, 20, 22 For some retinal cell types, such as bipolar, ganglion or glial cells, where existing AAV serotypes may not be particularly efficient, methodologies such as directed evolution have been employed to generate novel serotypes which may provide vectors with predilections for these cells. [14] [15] [16] AAV2/rh10, used in this study, was isolated from nonhuman primates (NHPs) by polymerase chain reaction (PCR) amplification of latent genomes. 9 Neither the receptor for AAV2/rh10 has been identified, nor the tropism of this capsid serotype fully elucidated but it has been shown to efficiently transduce cells of the central nervous system. Cearley and Wolfe 23 demonstrated that AAV2/rh10 can transduce neurons, with greater efficacy than AAV2/7, 2/8, and 2/9 in adult mouse brains. Hu et al. 24 reported that reporter gene expression was ~20-fold higher when transduced with AAV2/rh10 compared with AAV2/8 in murine brain transduced at p2. Long-term expression and safety of AAV2/rh10 has also been observed in the brains of rats and NHPs. 25 In addition, AAV2/rh10 has been shown to transduce some retinal cell types including ganglion cells and RPE cells following intravitreal injection. 26 An AAV2/rh10 expressing an antihuman vascular endothelial growth factor antibody transgene, Bevacizumab, has also been shown to transduce RPE cells, when administered intravitreally, and to suppress neovascularization in a murine model for age-related macular degeneration. 27 In addition, Watanabe et al. 20 Because retinal degenerations frequently originate from genetic mutations primarily affecting photoreceptors, it is pertinent to identify vectors that efficiently transduce and express gene therapies in these cells. Given the potency of AAV2/rh10 to transduce neurons, including some retinal cell types, it was of value to address whether this serotype might target photoreceptors efficiently and, moreover, might provide clinically relevant benefit in a murine model of retinal degeneration. Earlier, we established significant rescue of the severe retinal degeneration present in a rhodopsin knockout mouse (Rho -/-28 ) when delivering a human rhodopsin (RHO) transgene via AAV2/5. 29 Improvement in the retention of rod photoreceptor cells and retinal architecture as well as retinal function was achieved in this study. In order to evaluate the efficacy of photoreceptor rescue using the AAV2/rh10 serotype in this study, we re-employed the Rho -/-murine model and expressed an efficient RHO replacement construct, 29 which utilizes an optimized murine rhodopsin promoter (BB24; Figure 1a ). As AAV2/8 is considered to be one of the most efficient serotypes for targeting photoreceptors in rodents, the efficacy of AAV2/rh10 transduction was directly compared to that of AAV2/8. Significant benefit was obtained from RHO replacement utilizing both AAV2/rh10 and AAV2/8 delivery via subretinal administration in this study. Of note this study reports an AAV2/ rh10-based gene therapy approach providing benefit to photoreceptor cells in a degenerating retina.
ReSUlTS
In order to compare the utility of AAV2/8 and AAV2/rh10 in photoreceptor gene therapy applications, the effects of rhodopsin gene replacement were analyzed in transgenic mice with a targeted disruption in the rhodopsin gene (Rho -/-mice 28 ) employing AAV2/8 or AAV2/rh10 for delivery. In the absence of rhodopsin, Rho -/-mice neither develop rod outer segments (OS) nor have a detectable rod-derived electroretinogram (ERG) at any stage of development. Because of the progressive loss of rods, the outer nuclear layer (ONL) has only one layer (of mostly cones) remaining by 3 months of age and no ONL at all by 6 months of age. Earlier, we utilized the Rho -/-model to optimize a rhodopsin replacement strategy employing AAV2/5; rescue of retinal structure and function was achieved in this study. 29 An effective rhodopsin replacement construct from this study (BB24, Figure 1a) 29 ) prior to injection; untreated eyes served as controls. Using these parameters, the transduced area (based on native EGFP fluorescence) was ~40-60% of the retina (see Supplementary Figure S1 ). Molecular, structural, and functional analyses of the retinas were undertaken using reverse transcription-quantitative real-time PCR (RT-qPCR), light and electron microscopy, ERG, and optometry.
RHO mRNA expression Total RNA was isolated from 3-month-old NHR+/-Rho -/-retinas 28, 30 (n = 4) and transduced Rho -/-retinas 1 and 6 weeks postdelivery of either RHO-2/8 or RHO-2/rh10 (n = 8-10). RHO mRNA expression was determined using RT-qPCR; β-actin mRNA expression was used as an internal control. Relative RHO mRNA levels normalized to expression in NHR+/-Rho -/-retinas are provided in Figure 1b . At 1 week postinjection, RHO expression levels from RHO-2/rh10 injected retinas (15.5 ± 5.1%) were approximately fivefold lower than from RHO-2/8 injected eyes (75.4 ± 44.1%), P < 0.001. At 6 weeks, no increase in expression from RHO-2/8 was observed compared to RHO-2/8 at 1 week. In contrast, significant increases in expression were observed with RHO-2/rh10 between 1 and 6 weeks (78.8 ± 33.0%; P < 0.001; Figure 1b ) such that expression levels of rhodopsin were not significantly different for the RHO-2/rh10 and RHO-2/8 serotypes by 6 weeks postinjection. Notably, expression levels of rhodopsin in Rho -/-retinas treated with RHO-2/rh10 and RHO-2/8 were ~75% of that in adult NHR+/-Rho -/-retinas 6 weeks postinjection. The difference between expression levels in NHR+/-Rho -/-and treated Rho -/-retinas was not statistically significant because of the high variation in the treated samples.
Histology
Histological analysis using light microscopy was undertaken at 3 and 6 months postinjection; the architecture of the photoreceptor layer, rhodopsin expression, and the general structure of the retina were evaluated (Figures 2-4) . At 3 months postinjection, the thickness of the ONL was 27.6 ± 5.5 μm (n = 4), 25.8 ± 7.2 μm (n = 4), and 4.4 ± 0.9 μm (n = 5) in RHO-2/8 or RHO-2/rh10 treated and control eyes, respectively (Figure 2a,b,c,g ). The ONL thickness in the AAV-treated eyes was significantly greater than that of the control eyes (P < 0.05), whereas the ONL thickness was not statistically different between RHO-2/8-and RHO-2/rh10-treated eyes. At 6 months postinjection, the thickness of the ONL was 21.9 ± 6.7 μm (n = 6) and 24.9 ± 4.1 μm (n = 6) in RHO-2/8-or RHO-2/ Retinas were harvested and RHO mRNA expression analyzed by RT-qPCR 1 and 6 weeks postinjection. β-Actin was used as an internal control. Relative expression levels are given as a percentage of levels in 3-month-old NHR+/-Rho-/-retinas (n = 4). ***P < 0.001 between RHO-2/8 and RHO-2/rh10 at 1 week; ***P < 0.001 between RHO-2/rh10 at 1 and 6 weeks. (Figure 3 ). At 3 months postinjection, the length of the IS was 19.0 ± 4.0 μm (n = 3) and 17.7 ± 2.9 μm (n = 3) in RHO-2/8-or RHO-2/rh10-treated retinas, respectively; they were not statistically different from each other (Figure 3a ,b,e). At 6 months postinjection, the length of the IS was 12.0 ± 2.2 μm (n = 6) and 12.7 ± 2.7 μm (n = 5) in RHO-2/8-or RHO-2/rh10-treated retinas ( Figure 3c ,d,e), respectively; they were not statistically different from each other but were shorter from corresponding values at 3 months ( Figure 4e ; P < 0.05). In comparison, the length of the IS was 23.8 ± 2.3 μm (n = 3) in the B6-EGFP (C57BL/6-Tg(CAG-EGFP)1Osb/J; stock number 003291; The Jackson Laboratory, Bar Harbor, ME) mouse at 6 months of age (data not shown). The B6-EGFP mice have normal retinas in which EGFP is expressed from the chicken β-actin promoter and cytomegalovirus enhancer and is present in the IS, thereby enabling comparison of the IS between B6-EGFP and AAVtreated Rho -/-mice. In order to analyze if the AAV treatment was well tolerated, the general structure of the retinas was also evaluated by hematoxylin and eosin staining at 3 and 6 months postinjection (n = 4-5; Figure 4 ). Apart from the beneficial changes in the architecture of the photoreceptor segments and ONL, no other changes were observed. In particular, no increase in the number of infiltrates was detected in RHO-2/8- (Figure 4b Ultrastructural analysis was performed 6 months postinjection (n = 2; Figures 5 and 6 ). In the retina of untreated Rho -/-mice, only , but also in the formation and survival of rod photoreceptor OS, which extended to the RPE. Note that OS is not present in the untreated Rho -/-retina at any stage. In contrast, clear OS structures were evident and contained correctly formed membrane disks in the RHO-2/8- (Figure 6c,d) and RHO-2/rh10- (Figure 6g,h) treated Rho -/-retinas. Connecting cilia with normal structure was also detected in these retinas (Figure 6b,f) .
ERG
ERGs were recorded at 2, 5, and 11 months postinjection; pure rod-derived b-waves ( Figure 7 ) and mixed rod/cone a-waves (see Supplementary Figure S2 (Figure 7b ), respectively. These were not statistically different from each other but were different from their corresponding values at 2 months postinjection (P < 0.001 and <0.01 for RHO-2/8-treated and RHO-2/rh10-treated eyes, respectively; Figure 7 ). Note that the untreated Rho -/-(control) eyes had no recordable rod-derived ERGs at any of the above-mentioned ages investigated (not shown).
At 2 months postinjection, means of mixed rod/cone a-wave amplitudes of 83.4 ± 16.5 μV (n = 8) and 82.4 ± 29.7 μV (n = 8) were recorded for RHO-2/8 and RHO-2/rh10 respectively (see Supplementary Figure S2 ). These were not statistically different from each other. At 5 months postinjection, means of a-wave amplitudes of 54.8 ± 29.2 μV (n = 4) and 43.8 ± 8.8 μV (n = 8) were recorded for RHO-2/8 and RHO-2/rh10 respectively (see Supplementary Figure  S2 ). These were not statistically different from each other but were noticeably lower than corresponding 2 month values; in the case of RHO-2/rh10 the corresponding values at 2 and 5 months postinjection differed significantly (P < 0.05; see Supplementary Figure S2 ). At 11 months postinjection, means of a-wave amplitudes of 27.5 ± 14.3 μV (n = 8) and 20.1 ± 6.5 μV (n = 4) were recorded for RHO-2/8 and RHO-2/rh10, respectively (see Supplementary Figure S2 ); again these were not statistically different from each other but were different from corresponding values at 2 months postinjection (P < 0.001).
Optomotry Functional vision was tested using a virtual optokinetic system 31 6 months postinjection. Using the optokinetic tracking response, the spatial frequency threshold (the spatial frequency of the grating at 100% contrast where tracking behavior is no longer observed) was determined as 0.309 ± 0.017 cyc/deg (n = 7) and 0.328 ± 0.062 cyc/deg (n = 6) for RHO-2/8-and RHO-2/rh10-transduced eyes (Figure 8 ). The spatial frequency thresholds were 0.427 ± 0.009 cyc/ deg (n = 6) for wild-type mice while untreated Rho -/-mice exhibited no tracking behavior (n = 6; Figure 8 ). Differences between RHO-2/8-and RHO-2/rh10-transduced eyes were not statistically significant; however, tracking responses between AAV-treated eyes compared with wild-type or control Rho -/-(untreated) eyes were significant (P < 0.01, Figure 8 ).
DISCUSSION
As the AAV constructs employed in this study utilize a rhodopsin promoter to drive transgene expression only in photoreceptor cells, 
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6 months a controlled comparative evaluation of the efficiency of transgene expression specifically in murine photoreceptors was undertaken. Using this approach we demonstrated the capacity of AAV2/rh10 to target mammalian photoreceptors efficiently following subretinal injection, attaining levels of transduction equal to AAV2/8. Indeed, the results suggest that both AAV2/8 and AAV2/rh10 provided similar levels of rescue of the retinal degeneration observed in Rho -/-mice. Earlier, we described the benefit in the Rho -/-model using an AAV2/5 serotype for gene delivery. 29 In that study, doses of AAV2/5 in a similar range to this study were employed. Notably, a similar magnitude of rescue was observed between the studies; therefore AAV2/5, AAV2/8, and AAV2/rh10 have now been shown in a murine retinal degeneration model to provide similar levels of efficacy following photoreceptor transduction. As AAV transduction is species-dependent, it remains to be established whether the efficacy of these serotypes established in mice directly translates to the humans. In this regard, it is notable that for other neuronal tissues such as motor neurons, AAV2/rh10 outperformed AAV serotypes such as AAV2 and AAV8, and moreover, the efficient transduction obtained in mice with AAV2/rh10 translated through to NHPs. 32 The results from this study suggest that AAV2/rh10 is a highly efficient serotype for gene delivery to mammalian photoreceptors, possibly providing an alternative to the frequently used AAV2/5 and AAV2/8 serotypes.
Interestingly, in this study, RHO-2/8 provided higher transgene expression levels at an earlier timepoint (1 week postsubretinal injection) than RHO-2/rh10 in the murine retina, indicating that the AAV2/8 serotype results in more rapid transgene expression in murine rod photoreceptor cells than the AAV2/rh10 serotype; however, expression levels from both serotypes are indistinguishable by 6 weeks post subretinal injection of vector (Figure 1b) . Early high expression, such as that achieved from AAV2/8, may be of particular value when testing therapies in rapidly degenerating disease models, such as the RHO Pro23His murine model of RP 30 , among others. However, given the severe degenerating nature of the Rho -/-mouse model used and the fact that rescue was obtained using both serotypes, the results suggest that rhodopsin expression mediated by AAV2/rh10 was sufficient to preserve photoreceptors after early subretinal administration (p3-4) of vector. RHO mRNA levels in the treated Rho -/-retinas were ~75% of levels in NHR+/-Rho -/-28,30 mice which express approximately the same level of rhodopsin mRNA as wild mice. 33 In this study, rhodopsin delivery mediated by both AAV2/8 and AAV/rh10 serotypes provided histological (analyzed by light and electron microscopy) and functional benefits (analyzed by ERG and optomotry) to the Rho -/-mouse. Indeed, similar levels of rescue with these two serotypes were observed up to 11 months following treatment (Figures 2, 3, and 5-8) . Although the rate of degeneration was reduced, ERG and histological analyses indicate that degeneration was not altogether arrested in treated mice. At this time it remains unclear what factor(s) are driving the retinal degeneration in the treated retinas. Because the treated area was up to approximately half of the total retinas, degeneration in the nontreated areas may have affected the treated regions. Notably, in a human gene therapy for LCA, while the therapy improved vision, the retinal degeneration was not stopped mirroring experiments in the canine model. 34 In addition to the observed rescue of the cellular architecture with both serotypes, similar low numbers of infiltrating cells were observed in untreated retinas and retinas treated with either AAV2/8 or AAV/rh10. Presence of infiltrates in the untreated Rho -/-retina is possibly related to the ongoing degeneration of the tissue. As the number of infiltrates was low and did not increase in the treated retinas, these results suggest that the administered AAV load, both in terms of serotype and quantity, is well tolerated in the murine retina. Earlier, AAV2/rh10 has been shown to be well tolerated in other neuronal tissues in NHPs. 32 Furthermore, AAV2/rh10 has been clinically tested in humans after intracerebral injection for mucopolysaccharidosis IIIA 35 and late infantile neuronal ceroid lipofuscinosis. 36 In an earlier study, 20 AAV2/rh10 was used to evaluate photoreceptor transduction after a p0 injection into the wild type mouse retina. Of note, in contrast to the efficient photoreceptor transduction and rescue of disease pathology obtained in this study using AAV2/rh10 in Rho -/-mice, photoreceptor transduction did not appear efficient, possibly because of the p0 delivery. 20 Many gene therapies are now entering clinical trial with the first EU-approved AAV therapy, Glybera, having obtained market approval. This therapy utilizes AAV1 to administer the lipoprotein lipase gene to the muscle of patients with lipoprotein lipase deficiency. Other AAV gene therapies tested in recent clinical trials have also been well tolerated in patients when administered using a similar regimen of immunosuppression; immunological responses, where present, were of short duration with no lasting ill effects. 37, 38 In the context of the retina, clinical trials to date for LCA and Choroideremia would suggest that AAV is well tolerated in the human eye after subretinal administration. [1] [2] [3] 6 Given the wide range of gene therapies for many different inherited ocular disorders currently in preclinical development, 39 there is a clear need for a repertoire of AAV vectors to deliver to this target tissue. Results from this study suggest that AAV2/rh10 should be considered as an efficient vector option for delivery to mammalian photoreceptors. Further studies in NHPs may be needed to identify the most optimal candidate serotype for gene transfer in humans.
Furthermore it is of note that recent studies employing gene delivery using AAV2/rh10 have demonstrated efficient dissemination and expression of the transgene throughout the spinal cord and certain regions of the brain. 23, 32, 40, 41 Notably, retinal degenerations frequently present as part of the clinical symptoms of syndromic disorders. For example, symptoms of Usher Syndrome include retinitis pigmentosa in conjunction with sensorineural deafness, whereas symptoms of Senior-Loken syndrome (a ciliopathy) include LCA, nephronophthisis, cerebellar ataxia, and skeletal abnormalities. For such disorders, dissemination of a gene therapeutic to multiple tissues and organs may be required. It is therefore of particular value to explore the various AAV serotype options that are available for such treatments. In this study, it has been established that AAV2/rh10 performs to a similar level as AAV2/8 in the context of gene delivery to mammalian photoreceptors. It has also been observed that AAV2/ rh10 can efficiently transduce a variety of other neuronal targets, e.g., in the brain and the spinal cord. 32, 40, 41 Indeed, in some of these cases, AAV2/rh10 has been shown to provide the highest levels of transgene expression, much higher than AAV2/8. 23, 24 Therefore, AAV2/rh10 may represent an AAV serotype that has significant potential for gene therapies for multifaceted disorders, where photoreceptor degeneration represents one of a collection of disease phenotypes.
MATeRIAlS AND MeTHODS

AAV production
pAAV-BB24 and pAAV-EGFP were constructed as described. 29 Recombinant AAV-EGFP was generated using a helper virus-free system as described.
33
AAV2/8-BB24 (RHO-2/8) and AAV2/rh10-BB24 (RHO-2/rh10) were prepared in the Research Vector Core, University of Pennsylvania. AAV2/8 capsid (GenBank sequence AY242997) and AAV2/rh10 capsid Genomic titers (DNase-resistant viral genomes per milliliter; vg/ml) were determined by qPCR. use of animals in ophthalmic and vision research as described. 33 In brief, newborn (p3-4) mice were anesthetized as described. 43 A small puncture was made in the sclera. A 34-gage blunt-ended microneedle attached to a 10-μl syringe (Hamilton) was inserted through the puncture, 5 × 10 9 vg of AAV in 0.6 μl PBS was administered to the subretinal space, and retinal detachment was induced. 33 RNA was isolated from whole retinas 1 and 6 weeks postinjection and RHO expression analyzed by RT-qPCR as described. 33 
Histology
Eyes were fixed in 4% paraformaldehyde and processed for fluorescent microscopy analysis as described. 43 Rhodopsin immunohistochemistry was carried out using 4D2 antirhodopsin primary (1/100 dilution 30 , provided by Dr. Robert Molday, Department of Biochemistry and Molecular Biology, University of British Columbia, Canada) and Cy3-conjugated antimouse secondary (1/400 dilution; Jackson Immuno Research, Newmarket, UK) antibodies. Rhodopsin label (Cy3), EGFP, and 4' ,6-diamidino-2-phenylindole (DAPI) signals were detected by fluorescent microscopy as described 44 ; corresponding images taken with different filter sets were overlaid. Hematoxylin and eosin staining was performed using Gill's hematoxylin and 1% alcoholic eosin Y. Histology measurements were carried out using Photoshop CS6 (Adobe Systems Software Ireland Ltd., Dublin, Ireland). Typically, images from two to three sections in the central part of the retina ~150 μm apart were analyzed in each eye.
Transmission electron microscopy analysis was performed as described. 29 In brief, eyes were fixed in 4% paraformaldehyde. Using the EGFP tracer, EGFP-positive areas from the central part of transduced retinas were excised and fixed in 2.5% glutaraldehyde in 0.1 M cacodylate buffer for 2 hours. Specimens were postfixed in 2% OsO 4 and embedded in Araldite.
Ultrastructural analyses were performed with a Tecnai 12 Bio-TWIN transmission electron microscope (FEI, Eindhoven, the Netherlands) and imaged with an SIS MegaView III camera (Olympus Soft Imaging Solutions, Munster, Germany).
ERG
ERG measurements were performed as described. 45 In brief, animals were dark adapted overnight and procedures were carried out under dim red light. A mixture of ketamine and xylazine (16 and 1.6 μg/10 g body weight, respectively) were administered i.p. for anesthesia; pupils were dilated with 1% cyclopentalate and 2.5% phenylephrine. ERG responses were recorded simultaneously from both eyes by means of goldwire electrodes (Roland Consulting, Brandenburg-Wiesbaden, Germany). Standardized flashes of light were presented in a Ganzfeld bowl. Rodisolated responses were recorded using a dim white flash (−25 dB of the maximal flash intensity, where the maximal flash intensity was 3 candelas/m 2 /s) presented in the dark-adapted state using a RetiScan RetiPort electrophysiology unit (Roland Consulting). Mixed rod/cone responses were then recorded to the maximal intensity flash (3 candelas/m 2 /s), presented in the dark-adapted state.
Optokinetic tracking response
Functional vision was tested using the optokinetic tracking response as described. 46 In brief, the spatial frequency thresholds (the point where the mouse no longer tracked the moving gratings) were determined by two independent researchers using a virtual optokinetic system (OptoMotry, CerebralMechanics, Lethbridge, AB, Canada). 31 
Statistical analysis
Mean and SD values of data sets were calculated. Statistical significance of differences between groups was determined using Mann-Whitney U-test, as normal distribution was not assumed (Data Desk 6.3.1, Data Description, New York); differences of P < 0.05 were considered statistically significant. 8 vg/eye of AAV2/5-EGFP tracer; untreated eyes served as controls. The optokinetic tracking response (spatial frequency threshold) was measured using a virtual optokinetic system 6 months postinjection. Bar chart represents the mean spatial frequency threshold established for RHO-2/8 and RHO-2/ rh10-treated (gray columns), age-matched untreated (black column), and wild-type mice (white column). Note that the untreated eyes had no tracking response and were assigned with a spatial frequency threshold of 0. Error bars represent SD values. ‡ P < 0.01 (compared with untreated eyes), **P < 0.01 (compared with wild-type eyes). 
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